Article Text

PDF
OP0019 Osteoarthritis, Drug Use and Risk of Cardiac Ischaemic Events: A Case-Control Study
  1. C. Pontes1,2,
  2. R. Morros2,3,
  3. J.R. Marsal4,5,
  4. F. de Abajo6,
  5. J.R. Castillo7,
  6. J. Rios8,
  7. X. Carné9,
  8. P. Du Souich10
  1. 1Unitat de Farmacologia Clínica, Hospital de Sabadell - Institut Universitari Parc Tauli, Sabadell
  2. 2Dept of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona
  3. 3SIDIAP - Sistema d'Informaciό pel Desenvolupament de la Investigaciό en Atenciό Primària, IDIAP Jordi Gol, Barcelona
  4. 4USR Lleida-Pirineu - SIDIAP, IDIAP Jordi Gol, Lleida
  5. 5Unitat d'Epidemiologia del Servei de Cardiologia, Hospital Universitari Vall d'Hebron, Barcelona
  6. 6Universidad de Alcalá, Hospital Universitario Príncipe de Asturias, Alcalá de Henares
  7. 7Hospital Universitario Virgen del Rocío, Sevilla
  8. 8Plataforma de Bioestadística i Gestiό de Dades, IDIBAPS - Hospital Clínic de Barcelona
  9. 9Hospital Clínic de Barcelona, Barcelona, Spain
  10. 10Faculté de Médecine - Université de Montréal, Montréal, Canada

Abstract

Background Recent controversies on the safety profile of drugs used to treat osteoarthritis (OA) have led to changes in clinical guidance for management (1).

Objectives To describe associations between the use of different OA drug therapies and the risk of cardiac ischemic events (CIE).

Methods We conducted a nested case-control study within a cohort of patients with clinically diagnosed OA (according to ICD10 codes in the SIDIAP database of primary care records for over 5 million people in Catalonia, Spain (2)). Cases were identified in the period between 2008 and 2012 through ICD10 codes of cardiac ischemic events (CIE) (AIM or unstable angina, fatal or not) and cross-checked with hospital discharge diagnosis; 3 controls without CIE were matched to each case by sex, age (±5 years), area and year (±2 years) of first diagnosis of OA. Data were linked with pharmacy invoicing information, encrypted and extracted for analysis. Exposure to NSAIDs, SYSADOAs, opioids, paracetamol and metamizole were analysed. Adjusted multivariate conditional logistic regression models were fitted to estimate odds ratio (OR) for CIE according to drug use.

Results We studied 5663 cases and 16989 matched controls. Cases had more morbidity and cardiovascular risk factors, but similar characteristics for OA and joint involvement. Significantly increased risks (OR 95%CI) were observed related to the use of non-selective NSAIDs (1.10 (95%CI 1.01 to 1.19)), in particular for diclofenac (1.16 (1.07 to 1.25)) and naproxen (1.14 (1.01 to 1.29)), and for opioid analgesics (1.13 (1.04 to 1.24)). SYSADOAS, paracetamol and metamizole showed no significant associations with CIE.

Conclusions In patients with OA, non-selective NSAIDs (diclofenac, naproxen) and opioid analgesics are associated to an increased risck of CV events. This should be considered for the management of OA patients with a high cardiovascular risk profile.

References

  1. National Institute for Health Care and Excellence. Osteoarthritis care and management in adults. National Institute for Health and Care Excellence (United Kingdom), 2014. www://www.nice.org.uk/guidance/cg177/resources/guidance-osteoarthritis-pdf (accessed 25th January 2015).

  2. Bolíbar B, Fina F, Morros R et al. SIDIAP database: electronic clinical records in Primary Care as a source of information for epidemiologic research. Med Clin (Barc) 2012;138(14):617-21.

Acknowledgements The study was funded by Bioibérica S.A.

Disclosure of Interest None declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.